Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Mróz P[au]:

Photodynamic therapy of cancer: an update. Agostinis P et al. CA Cancer J Clin. (2011)

Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism. Mroz PA et al. Mol Metab. (2019)

Molecular elements in FGF19 and FGF21 defining KLB/FGFR activity and specificity. Agrawal A et al. Mol Metab. (2018)

Search results

Items: 1 to 50 of 64

1.

A three-dimensional map of the Milky Way using classical Cepheid variable stars.

Skowron DM, Skowron J, Mróz P, Udalski A, Pietrukowicz P, Soszyński I, Szymański MK, Poleski R, Kozłowski S, Ulaczyk K, Rybicki K, Iwanek P.

Science. 2019 Aug 2;365(6452):478-482. doi: 10.1126/science.aau3181.

PMID:
31371611
2.

Next generation sequencing for clinical diagnostics: Five year experience of an academic laboratory.

Hartman P, Beckman K, Silverstein K, Yohe S, Schomaker M, Henzler C, Onsongo G, Lam HC, Munro S, Daniel J, Billstein B, Deshpande A, Hauge A, Mroz P, Lee W, Holle J, Wiens K, Karnuth K, Kemmer T, Leary M, Michel S, Pohlman L, Thayanithy V, Nelson A, Bower M, Thyagarajan B.

Mol Genet Metab Rep. 2019 Mar 1;19:100464. doi: 10.1016/j.ymgmr.2019.100464. eCollection 2019 Jun.

3.

The Correlation of Blood Parameters with Size in Cases of Neoplastic Tumor

Wolny-Rokicka E, Wydmański J, Tukiendorf A, Mróz P, Gramacka K, Namysł-Kaletka A, Lipiński J, Zembroń-Łacny A.

Asian Pac J Cancer Prev. 2019 Jan 25;20(1):53-57.

4.

Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism.

Mroz PA, Finan B, Gelfanov V, Yang B, Tschöp MH, DiMarchi RD, Perez-Tilve D.

Mol Metab. 2019 Feb;20:51-62. doi: 10.1016/j.molmet.2018.12.001. Epub 2018 Dec 5.

5.

Appraisal of Basic-Hemostatic Markers in Lung Cancer Patients During Follow-Up Care After Radiotherapy Treatment.

Wolny-Rokicka EI, Wydmański J, Tukiendorf A, Mróz P, Zembroń-Łacny A.

Med Sci Monit. 2018 Nov 27;24:8577-8582. doi: 10.12659/MSM.910280.

6.

DNA Methylation Changes in Lung Immune Cells Are Associated with Granulomatous Lung Disease.

Yang IV, Konigsberg I, MacPhail K, Li L, Davidson EJ, Mroz PM, Hamzeh N, Gillespie M, Silveira LJ, Fingerlin TE, Maier LA.

Am J Respir Cell Mol Biol. 2019 Jan;60(1):96-105. doi: 10.1165/rcmb.2018-0177OC.

PMID:
30141971
7.

Molecular elements in FGF19 and FGF21 defining KLB/FGFR activity and specificity.

Agrawal A, Parlee S, Perez-Tilve D, Li P, Pan J, Mroz PA, Kruse Hansen AM, Andersen B, Finan B, Kharitonenkov A, DiMarchi RD.

Mol Metab. 2018 Jul;13:45-55. doi: 10.1016/j.molmet.2018.05.003. Epub 2018 May 11.

8.

No large population of unbound or wide-orbit Jupiter-mass planets.

Mróz P, Udalski A, Skowron J, Poleski R, Kozłowski S, Szymański MK, Soszyński I, Wyrzykowski Ł, Pietrukowicz P, Ulaczyk K, Skowron D, Pawlak M.

Nature. 2017 Aug 10;548(7666):183-186. doi: 10.1038/nature23276. Epub 2017 Jul 24.

PMID:
28738410
9.

Design features for optimization of tetrapyrrole macrocycles as antimicrobial and anticancer photosensitizers.

Martinez De Pinillos Bayona A, Mroz P, Thunshelle C, Hamblin MR.

Chem Biol Drug Des. 2017 Feb;89(2):192-206. doi: 10.1111/cbdd.12792. Review.

10.

Native Design of Soluble, Aggregation-Resistant Bioactive Peptides: Chemical Evolution of Human Glucagon.

Mroz PA, Perez-Tilve D, Liu F, Mayer JP, DiMarchi RD.

ACS Chem Biol. 2016 Dec 16;11(12):3412-3420. Epub 2016 Nov 8.

PMID:
27797473
11.

The awakening of a classical nova from hibernation.

Mróz P, Udalski A, Pietrukowicz P, Szymański MK, Soszyński I, Wyrzykowski Ł, Poleski R, Kozłowski S, Skowron J, Ulaczyk K, Skowron D, Pawlak M.

Nature. 2016 Sep 29;537(7622):649-651. doi: 10.1038/nature19066. Epub 2016 Aug 17.

PMID:
27533036
12.

Pyridyl-alanine as a Hydrophilic, Aromatic Element in Peptide Structural Optimization.

Mroz PA, Perez-Tilve D, Liu F, Gelfanov V, DiMarchi RD, Mayer JP.

J Med Chem. 2016 Sep 8;59(17):8061-7. doi: 10.1021/acs.jmedchem.6b00840. Epub 2016 Aug 25.

PMID:
27509198
13.

Nationwide survey on volunteers' training in hospice and palliative care in Poland.

Pawłowski L, Lichodziejewska-Niemierko M, Pawłowska I, Leppert W, Mróz P.

BMJ Support Palliat Care. 2019 Sep;9(3):e25. doi: 10.1136/bmjspcare-2015-000984. Epub 2016 Jul 29.

PMID:
27474087
14.

Beryllium-induced lung disease exhibits expression profiles similar to sarcoidosis.

Li L, Silveira LJ, Hamzeh N, Gillespie M, Mroz PM, Mayer AS, Fingerlin TE, Maier LA.

Eur Respir J. 2016 Jun;47(6):1797-808. doi: 10.1183/13993003.01469-2015. Epub 2016 Apr 21.

15.

Extremely metal-poor stars from the cosmic dawn in the bulge of the Milky Way.

Howes LM, Casey AR, Asplund M, Keller SC, Yong D, Nataf DM, Poleski R, Lind K, Kobayashi C, Owen CI, Ness M, Bessell MS, Da Costa GS, Schmidt BP, Tisserand P, Udalski A, Szymański MK, Soszyński I, Pietrzyński G, Ulaczyk K, Wyrzykowski Ł, Pietrukowicz P, Skowron J, Kozłowski S, Mróz P.

Nature. 2015 Nov 26;527(7579):484-7. doi: 10.1038/nature15747. Epub 2015 Nov 11.

PMID:
26560034
16.

Beryllium increases the CD14(dim)CD16+ subset in the lung of chronic beryllium disease.

Li L, Hamzeh N, Gillespie M, Elliott J, Wang J, Gottschall EB, Mroz PM, Maier LA.

PLoS One. 2015 Feb 17;10(2):e0117276. doi: 10.1371/journal.pone.0117276. eCollection 2015.

17.

p38 Mitogen-Activated Protein Kinase in beryllium-induced dendritic cell activation.

Li L, Huang Z, Gillespie M, Mroz PM, Maier LA.

Hum Immunol. 2014 Dec;75(12):1155-62. doi: 10.1016/j.humimm.2014.10.010. Epub 2014 Oct 22.

18.

Efficacy of mycophenolate mofetil in sarcoidosis.

Hamzeh N, Voelker A, Forssén A, Gottschall EB, Rose C, Mroz P, Maier LA.

Respir Med. 2014 Nov;108(11):1663-9. doi: 10.1016/j.rmed.2014.09.013. Epub 2014 Sep 28.

19.

Exoplanet detection. A terrestrial planet in a ~1-AU orbit around one member of a ~15-AU binary.

Gould A, Udalski A, Shin IG, Porritt I, Skowron J, Han C, Yee JC, Kozłowski S, Choi JY, Poleski R, Wyrzykowski Ł, Ulaczyk K, Pietrukowicz P, Mróz P, Szymański MK, Kubiak M, Soszyński I, Pietrzyński G, Gaudi BS, Christie GW, Drummond J, McCormick J, Natusch T, Ngan H, Tan TG, Albrow M, DePoy DL, Hwang KH, Jung YK, Lee CU, Park H, Pogge RW, Abe F, Bennett DP, Bond IA, Botzler CS, Freeman M, Fukui A, Fukunaga D, Itow Y, Koshimoto N, Larsen P, Ling CH, Masuda K, Matsubara Y, Muraki Y, Namba S, Ohnishi K, Philpott L, Rattenbury NJ, Saito T, Sullivan DJ, Sumi T, Suzuki D, Tristram PJ, Tsurumi N, Wada K, Yamai N, Yock PC, Yonehara A, Shvartzvald Y, Maoz D, Kaspi S, Friedmann M.

Science. 2014 Jul 4;345(6192):46-9. doi: 10.1126/science.1251527.

20.

5-Aza-2'-deoxycytidine potentiates antitumour immune response induced by photodynamic therapy.

Wachowska M, Gabrysiak M, Muchowicz A, Bednarek W, Barankiewicz J, Rygiel T, Boon L, Mroz P, Hamblin MR, Golab J.

Eur J Cancer. 2014 May;50(7):1370-81. doi: 10.1016/j.ejca.2014.01.017. Epub 2014 Feb 18.

21.

Photodynamic therapy of murine mastocytoma induces specific immune responses against the cancer/testis antigen P1A.

Mroz P, Vatansever F, Muchowicz A, Hamblin MR.

Cancer Res. 2013 Nov 1;73(21):6462-70. doi: 10.1158/0008-5472.CAN-11-2572. Epub 2013 Sep 26.

22.

Photodynamic therapy plus regulatory T-cell depletion produces immunity against a mouse tumour that expresses a self-antigen.

Reginato E, Mroz P, Chung H, Kawakubo M, Wolf P, Hamblin MR.

Br J Cancer. 2013 Oct 15;109(8):2167-74. doi: 10.1038/bjc.2013.580. Epub 2013 Sep 24.

23.

CpG oligodeoxynucleotide as immune adjuvant enhances photodynamic therapy response in murine metastatic breast cancer.

Xia Y, Gupta GK, Castano AP, Mroz P, Avci P, Hamblin MR.

J Biophotonics. 2014 Nov;7(11-12):897-905. doi: 10.1002/jbio.201300072. Epub 2013 Aug 7.

24.

Vitamin D Receptor Gene BsmI Polymorphism in Polish Patients with Systemic Lupus Erythematosus.

Kaleta B, Bogaczewicz J, Robak E, Sysa-Jędrzejowska A, Wrzosek M, Szubierajska W, Mróz P, Lukaszkiewicz J, Woźniacka A.

ISRN Endocrinol. 2013 Jun 18;2013:427818. doi: 10.1155/2013/427818. Print 2013.

25.

Central pathology review for phase III clinical trials: the enabling effect of virtual microscopy.

Mroz P, Parwani AV, Kulesza P.

Arch Pathol Lab Med. 2013 Apr;137(4):492-5. doi: 10.5858/arpa.2012-0093-RA.

PMID:
23544938
26.

Linezolid and vancomycin decrease the therapeutic effect of methylene blue-photodynamic therapy in a mouse model of MRSA bacterial arthritis.

Tanaka M, Mroz P, Dai T, Huang L, Morimoto Y, Kinoshita M, Yoshihara Y, Shinomiya N, Seki S, Nemoto K, Hamblin MR.

Photochem Photobiol. 2013 May-Jun;89(3):679-82. doi: 10.1111/php.12040. Epub 2013 Feb 19.

27.

Photodynamic Therapy for Cancer and for Infections: What Is the Difference?

Sharma SK, Mroz P, Dai T, Huang YY, St Denis TG, Hamblin MR.

Isr J Chem. 2012 Sep;52(8-9):691-705.

28.

Cellular and vascular effects of the photodynamic agent temocene are modulated by the delivery vehicle.

García-Díaz M, Kawakubo M, Mroz P, Sagristà ML, Mora M, Nonell S, Hamblin MR.

J Control Release. 2012 Sep 10;162(2):355-63. doi: 10.1016/j.jconrel.2012.07.025. Epub 2012 Jul 27.

29.

Photodynamic therapy can induce a protective innate immune response against murine bacterial arthritis via neutrophil accumulation.

Tanaka M, Mroz P, Dai T, Huang L, Morimoto Y, Kinoshita M, Yoshihara Y, Nemoto K, Shinomiya N, Seki S, Hamblin MR.

PLoS One. 2012;7(6):e39823. doi: 10.1371/journal.pone.0039823. Epub 2012 Jun 26.

30.

EphA2 is a critical oncogene in melanoma.

Udayakumar D, Zhang G, Ji Z, Njauw CN, Mroz P, Tsao H.

Oncogene. 2011 Dec 15;30(50):4921-9. doi: 10.1038/onc.2011.210. Epub 2011 Jun 13.

31.

Intraperitoneal photodynamic therapy mediated by a fullerene in a mouse model of abdominal dissemination of colon adenocarcinoma.

Mroz P, Xia Y, Asanuma D, Konopko A, Zhiyentayev T, Huang YY, Sharma SK, Dai T, Khan UJ, Wharton T, Hamblin MR.

Nanomedicine. 2011 Dec;7(6):965-74. doi: 10.1016/j.nano.2011.04.007. Epub 2011 May 19.

32.

Photodynamic therapy of cancer: an update.

Agostinis P, Berg K, Cengel KA, Foster TH, Girotti AW, Gollnick SO, Hahn SM, Hamblin MR, Juzeniene A, Kessel D, Korbelik M, Moan J, Mroz P, Nowis D, Piette J, Wilson BC, Golab J.

CA Cancer J Clin. 2011 Jul-Aug;61(4):250-81. doi: 10.3322/caac.20114. Epub 2011 May 26. Review.

33.

Combination approaches to potentiate immune response after photodynamic therapy for cancer.

St Denis TG, Aziz K, Waheed AA, Huang YY, Sharma SK, Mroz P, Hamblin MR.

Photochem Photobiol Sci. 2011 May;10(5):792-801. doi: 10.1039/c0pp00326c. Epub 2011 Apr 9. Review.

34.

The immunosuppressive side of PDT.

Mroz P, Hamblin MR.

Photochem Photobiol Sci. 2011 May;10(5):751-8. doi: 10.1039/c0pp00345j. Epub 2011 Mar 24. Review.

35.

Cell death pathways in photodynamic therapy of cancer.

Mroz P, Yaroslavsky A, Kharkwal GB, Hamblin MR.

Cancers (Basel). 2011;3(2):2516-39. doi: 10.3390/cancers3022516.

36.

Photodynamic therapy of tumors can lead to development of systemic antigen-specific immune response.

Mroz P, Szokalska A, Wu MX, Hamblin MR.

PLoS One. 2010 Dec 14;5(12):e15194. doi: 10.1371/journal.pone.0015194.

37.

Stimulation of anti-tumor immunity by photodynamic therapy.

Mroz P, Hashmi JT, Huang YY, Lange N, Hamblin MR.

Expert Rev Clin Immunol. 2011 Jan;7(1):75-91. doi: 10.1586/eci.10.81. Review.

38.

Stable synthetic cationic bacteriochlorins as selective antimicrobial photosensitizers.

Huang L, Huang YY, Mroz P, Tegos GP, Zhiyentayev T, Sharma SK, Lu Z, Balasubramanian T, Krayer M, Ruzié C, Yang E, Kee HL, Kirmaier C, Diers JR, Bocian DF, Holten D, Lindsey JS, Hamblin MR.

Antimicrob Agents Chemother. 2010 Sep;54(9):3834-41. doi: 10.1128/AAC.00125-10. Epub 2010 Jul 12.

39.

Dye-enhanced multimodal confocal microscopy for noninvasive detection of skin cancers in mouse models.

Park J, Mroz P, Hamblin MR, Yaroslavsky AN.

J Biomed Opt. 2010 Mar-Apr;15(2):026023. doi: 10.1117/1.3394301.

40.

In vitro photodynamic therapy and quantitative structure-activity relationship studies with stable synthetic near-infrared-absorbing bacteriochlorin photosensitizers.

Huang YY, Mroz P, Zhiyentayev T, Sharma SK, Balasubramanian T, Ruzié C, Krayer M, Fan D, Borbas KE, Yang E, Kee HL, Kirmaier C, Diers JR, Bocian DF, Holten D, Lindsey JS, Hamblin MR.

J Med Chem. 2010 May 27;53(10):4018-27. doi: 10.1021/jm901908s.

41.

Stable synthetic bacteriochlorins overcome the resistance of melanoma to photodynamic therapy.

Mroz P, Huang YY, Szokalska A, Zhiyentayev T, Janjua S, Nifli AP, Sherwood ME, Ruzié C, Borbas KE, Fan D, Krayer M, Balasubramanian T, Yang E, Kee HL, Kirmaier C, Diers JR, Bocian DF, Holten D, Lindsey JS, Hamblin MR.

FASEB J. 2010 Sep;24(9):3160-70. doi: 10.1096/fj.09-152587. Epub 2010 Apr 12.

42.

On the use of experimental diets for physiological studies of hydrozoans.

Dudgeon S, Benes KM, Krueger SA, Kübler J, Mroz P, Slaughter CT.

J Mar Biol Assoc U K. 2009 Feb 1;89(1):83-88.

43.

Photophysical Characterization of Imidazolium-Substituted Pd(II), In(III), and Zn(II) Porphyrins as Photosensitizers for Photodynamic Therapy.

Kee HL, Bhaumik J, Diers JR, Mroz P, Hamblin MR, Bocian DF, Lindsey JS, Holten D.

J Photochem Photobiol A Chem. 2008 Dec 15;200(2-3):346-355. No abstract available.

44.

Proteasome inhibition potentiates antitumor effects of photodynamic therapy in mice through induction of endoplasmic reticulum stress and unfolded protein response.

Szokalska A, Makowski M, Nowis D, Wilczynski GM, Kujawa M, Wójcik C, Mlynarczuk-Bialy I, Salwa P, Bil J, Janowska S, Agostinis P, Verfaillie T, Bugajski M, Gietka J, Issat T, Glodkowska E, Mrówka P, Stoklosa T, Hamblin MR, Mróz P, Jakóbisiak M, Golab J.

Cancer Res. 2009 May 15;69(10):4235-43. doi: 10.1158/0008-5472.CAN-08-3439. Epub 2009 May 12.

45.

Imidazole metalloporphyrins as photosensitizers for photodynamic therapy: role of molecular charge, central metal and hydroxyl radical production.

Mroz P, Bhaumik J, Dogutan DK, Aly Z, Kamal Z, Khalid L, Kee HL, Bocian DF, Holten D, Lindsey JS, Hamblin MR.

Cancer Lett. 2009 Sep 8;282(1):63-76. doi: 10.1016/j.canlet.2009.02.054. Epub 2009 Apr 5.

46.

Photodynamic therapy plus low-dose cyclophosphamide generates antitumor immunity in a mouse model.

Castano AP, Mroz P, Wu MX, Hamblin MR.

Proc Natl Acad Sci U S A. 2008 Apr 8;105(14):5495-500. doi: 10.1073/pnas.0709256105. Epub 2008 Mar 31.

47.

Photodynamic therapy with fullerenes.

Mroz P, Tegos GP, Gali H, Wharton T, Sarna T, Hamblin MR.

Photochem Photobiol Sci. 2007 Nov;6(11):1139-49. Epub 2007 Oct 8. Review.

48.

Functionalized fullerenes mediate photodynamic killing of cancer cells: Type I versus Type II photochemical mechanism.

Mroz P, Pawlak A, Satti M, Lee H, Wharton T, Gali H, Sarna T, Hamblin MR.

Free Radic Biol Med. 2007 Sep 1;43(5):711-9. Epub 2007 May 10.

49.

Macrophage-targeted photosensitizer conjugate delivered by intratumoral injection.

Anatelli F, Mroz P, Liu Q, Yang C, Castano AP, Swietlik E, Hamblin MR.

Mol Pharm. 2006 Nov-Dec;3(6):654-64.

50.

Photodynamic therapy and anti-tumour immunity.

Castano AP, Mroz P, Hamblin MR.

Nat Rev Cancer. 2006 Jul;6(7):535-45. Review.

Supplemental Content

Support Center